1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Jackson, P.J.
Mcnulty, J.C.
Yang, Y.K.
Thompson, D.A.
Chai, B.
Gantz, I.
Barsh, G.S.
Millhauser, G.M.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
41
7565
7572
10.1021/bi012000x
12056887
Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity.
2002
US
Biochemistry
BICHAW
0033
0006-2960
40
15520
15527
10.1021/bi0117192
High Resolution NMR Structure of the Chemically-Synthesized Melanocortin Receptor Binding Domain of Agrp(87-132) of the Agouti-Related Protein.
2001
10.2210/pdb1mr0/pdb
pdb_00001mr0
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
THIS IS A RATIONALLY MINIMIZED FRAGMENT OF THE FULLY ACTIVE C-TERMINAL DOMAIN OF THE HUMAN AGOUTI-RELATED PROTEIN AGRP(87-132). THIS FRAGMENT HAS REMOVED FROM IT THE LARGELY DISORDERED C-TERMINAL 12 RESIDUES, YET RETAINS THE SAME BASIC STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF THE LARGER FRAGMENT.
3912.590
AGOUTI RELATED PROTEIN
RESIDUES 87-120
C105A
1
syn
polymer
no
no
CVRLHESCLGQQVPCCDPAATCYCRFFNAFCYCR
CVRLHESCLGQQVPCCDPAATCYCRFFNAFCYCR
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2002-10-02
1
1
2008-04-28
1
2
2011-07-13
1
3
2021-10-27
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_struct_ref_seq_dif.details
2002-10-02
SPRSDE
AGRP(87-132)
AGRP(87-120:C105A) Non-superimposed structures, same structure family
RCSB
Y
RCSB
2002-09-17
REL
THE PROTEIN WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PROTEIN IS NATURALLY FOUND IN HOMO SAPIENS. THE SYNTHETIC METHOD IS STANDARD SOLID-PHASE SYNTHESIS FOLLOWED BY AQUEOUS OXIDATIVE FOLDING.
sample
THE NOESY, TOCSY AND DQF-COSY EXPERIMENTS WERE PERFORMED AT 800 MHZ; THE HX STUDY WAS CONDUCTED AT 500 MHZ.
target function
1000
40
2D-NOESY
DQF-COSY
TOCSY
TOCSY(HX)
20 mM PERDEUTERATED ACETIC ACID
5.0
1
atm
288
K
200 mM PERDEUTERATED ACETIC ACID
4.0
1
atm
288
K
STRUCTURE CALCULATIONS WERE ASSISTED WITH AUTOMATED ASSIGNMENT. FINAL STRUCTURES WERE CALCULATED USING 602 NOE-BASED UPPER LIMIT RESTRAINTS AND 23 ALPHA-TO- AMIDE 3-BOND J-COUPLING CONSTANTS.
torsion angle dynamics
1
lowest target function
1.7 MM AGRP(87-120 NATURAL ABUNDANCE OF ALL NUCLEI.
pH 5.0 20 mM PERDEUTERATED ACETIC ACID
1.6 MM AGRP(87-120; C105A), NATURAL ABUNDANCE OF ALL NUCLEI.
pH 4.0 200 mM PERDEUTERATED ACETIC ACID
Krish Krishamurthy, Evan Williams, Steve Cheathum, Frtis Vosman, Dan Iverson, Michael Carlisle, Dan Steele, James Welch
collection
VNMR
6.1B
Department of Chemistry,Carlsberg Laboratory, Copenhagen, Denmark
processing
MNMR
940501
Guntert, P., Mumenthaler, C., and Wuthrich, K.
structure solution
DYANA
1.5
Bartels, C., Xia, T. H., Billeter, M., Guntert, P., and Wuthrich, K.
data analysis
XEASY
1.2
Guntert, P., Mumenthaler, C., and Wuthrich, K.
refinement
DYANA
1.5
800
Varian
UNITYPLUS
500
Varian
UNITYPLUS
CYS
1
n
1
CYS
1
A
VAL
2
n
2
VAL
2
A
ARG
3
n
3
ARG
3
A
LEU
4
n
4
LEU
4
A
HIS
5
n
5
HIS
5
A
GLU
6
n
6
GLU
6
A
SER
7
n
7
SER
7
A
CYS
8
n
8
CYS
8
A
LEU
9
n
9
LEU
9
A
GLY
10
n
10
GLY
10
A
GLN
11
n
11
GLN
11
A
GLN
12
n
12
GLN
12
A
VAL
13
n
13
VAL
13
A
PRO
14
n
14
PRO
14
A
CYS
15
n
15
CYS
15
A
CYS
16
n
16
CYS
16
A
ASP
17
n
17
ASP
17
A
PRO
18
n
18
PRO
18
A
ALA
19
n
19
ALA
19
A
ALA
20
n
20
ALA
20
A
THR
21
n
21
THR
21
A
CYS
22
n
22
CYS
22
A
TYR
23
n
23
TYR
23
A
CYS
24
n
24
CYS
24
A
ARG
25
n
25
ARG
25
A
PHE
26
n
26
PHE
26
A
PHE
27
n
27
PHE
27
A
ASN
28
n
28
ASN
28
A
ALA
29
n
29
ALA
29
A
PHE
30
n
30
PHE
30
A
CYS
31
n
31
CYS
31
A
TYR
32
n
32
TYR
32
A
CYS
33
n
33
CYS
33
A
ARG
34
n
34
ARG
34
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
TYR
23
A
N
TYR
23
A
O
TYR
32
A
O
TYR
32
5
A
A
O
H
VAL
CYS
2
16
1.52
7
A
A
O
H
VAL
CYS
2
16
1.58
8
A
A
H
OE1
ARG
GLU
3
6
1.55
9
A
A
O
H
VAL
CYS
2
16
1.56
12
A
A
H
OE1
ARG
GLU
3
6
1.52
13
A
A
H
OE1
ARG
GLU
3
6
1.57
15
A
A
O
H
VAL
CYS
2
16
1.53
19
A
A
O
H
VAL
CYS
2
16
1.54
22
A
A
O
H
VAL
CYS
2
16
1.55
23
A
A
H
O
VAL
PRO
2
14
1.59
23
A
A
O
H
VAL
CYS
2
16
1.59
26
A
A
O
H
VAL
CYS
2
16
1.57
29
A
A
H
OE1
ARG
GLU
3
6
1.54
31
A
A
O
H
VAL
CYS
2
16
1.50
31
A
A
H
O
VAL
PRO
2
14
1.57
33
A
A
HG1
O
THR
ARG
21
34
1.59
36
A
A
O
H
VAL
CYS
2
16
1.50
38
A
A
H
O
VAL
PRO
2
14
1.54
40
A
A
O
H
VAL
CYS
2
16
1.52
1
A
HIS
5
-84.40
46.37
1
A
SER
7
-39.46
156.54
1
A
LEU
9
-38.71
115.59
1
A
CYS
22
-65.92
91.22
1
A
PHE
26
-90.35
-156.64
1
A
ALA
29
-148.56
-85.50
2
A
HIS
5
-86.09
45.62
2
A
SER
7
-37.61
148.89
2
A
CYS
22
-61.15
84.43
2
A
PHE
26
-83.58
-154.68
2
A
ALA
29
-155.79
-72.62
3
A
HIS
5
-86.67
45.43
3
A
SER
7
-32.00
141.43
3
A
PHE
26
-78.66
-156.39
3
A
ALA
29
-155.59
-79.80
4
A
HIS
5
-93.35
44.75
4
A
SER
7
-37.16
154.56
4
A
CYS
22
-60.58
84.35
4
A
PHE
26
-80.72
-155.60
4
A
ALA
29
-155.42
-80.01
5
A
HIS
5
-87.96
45.87
5
A
SER
7
-36.97
154.61
5
A
LEU
9
-39.91
117.43
5
A
CYS
22
-61.23
82.32
5
A
PHE
26
-91.31
-157.13
5
A
ALA
29
-155.89
-39.17
6
A
HIS
5
-97.17
47.15
6
A
SER
7
-35.14
150.95
6
A
CYS
22
-62.01
83.60
6
A
PHE
26
-80.31
-156.66
6
A
ALA
29
-155.43
-79.27
7
A
HIS
5
-85.16
45.61
7
A
SER
7
-36.33
151.56
7
A
CYS
22
-63.96
85.31
7
A
PHE
26
-80.98
-156.13
7
A
ALA
29
-155.60
-78.11
8
A
HIS
5
-84.99
47.14
8
A
SER
7
-34.09
149.30
8
A
CYS
22
-61.85
83.22
8
A
PHE
26
-80.38
-156.38
8
A
ALA
29
-155.57
-79.44
9
A
HIS
5
-95.57
48.68
9
A
SER
7
-40.38
157.38
9
A
LEU
9
-47.77
106.10
9
A
CYS
22
-57.81
84.63
9
A
PHE
26
-80.13
-156.23
9
A
ALA
29
-155.51
-79.04
10
A
HIS
5
-92.25
46.57
10
A
SER
7
-42.08
158.39
10
A
LEU
9
-45.07
107.29
10
A
PRO
18
-75.09
-83.62
10
A
ALA
19
-84.32
46.15
10
A
CYS
22
-58.38
86.32
10
A
PHE
26
-80.75
-156.23
10
A
ALA
29
-155.42
-72.45
11
A
HIS
5
-84.94
45.81
11
A
SER
7
-37.57
153.60
11
A
LEU
9
-37.57
116.31
11
A
ALA
19
-91.82
30.99
11
A
CYS
22
-61.37
80.08
11
A
PHE
26
-116.04
-165.91
11
A
ALA
29
-155.57
-94.91
12
A
HIS
5
-86.27
46.13
12
A
SER
7
-34.96
150.91
12
A
CYS
22
-60.92
82.87
12
A
PHE
26
-96.95
-156.19
12
A
ALA
29
-156.03
-39.79
13
A
HIS
5
-84.84
45.36
13
A
SER
7
-35.36
145.75
13
A
CYS
22
-60.95
84.80
13
A
PHE
26
-79.55
-154.53
13
A
ASN
28
-146.91
29.05
13
A
ALA
29
-96.04
-84.87
14
A
HIS
5
-89.98
44.48
14
A
SER
7
-37.23
154.81
14
A
LEU
9
-37.14
111.81
14
A
PRO
18
-74.93
-83.81
14
A
CYS
22
-59.86
86.47
14
A
PHE
26
-81.02
-156.42
14
A
ALA
29
-155.39
-70.51
15
A
HIS
5
-86.49
45.05
15
A
SER
7
-39.41
153.39
15
A
LEU
9
-37.51
119.75
15
A
CYS
22
-64.26
84.18
15
A
PHE
26
-79.71
-156.01
15
A
ALA
29
-155.55
-79.78
16
A
HIS
5
-85.58
45.22
16
A
SER
7
-34.26
143.97
16
A
ALA
19
-92.69
32.99
16
A
CYS
22
-60.61
80.63
16
A
PHE
26
-113.67
-165.00
16
A
ALA
29
-155.64
-94.98
17
A
HIS
5
-88.94
45.89
17
A
SER
7
-34.76
150.91
17
A
ALA
19
-92.06
30.49
17
A
CYS
22
-63.67
79.47
17
A
PHE
26
-87.93
-155.89
17
A
ALA
29
-150.12
-84.42
18
A
HIS
5
-96.81
45.83
18
A
SER
7
-46.69
152.95
18
A
CYS
22
-60.42
81.68
18
A
PHE
26
-80.86
-155.75
18
A
ALA
29
-155.79
-70.46
19
A
HIS
5
-85.75
46.63
19
A
SER
7
-39.11
155.13
19
A
LEU
9
-36.93
127.02
19
A
CYS
22
-60.04
83.96
19
A
PHE
26
-81.61
-155.90
19
A
ALA
29
-155.64
-80.26
20
A
HIS
5
-84.85
46.03
20
A
SER
7
-37.76
155.93
20
A
CYS
22
-66.84
89.72
20
A
PHE
26
-89.67
-154.47
20
A
ALA
29
-145.04
-78.79
21
A
HIS
5
-84.04
47.15
21
A
SER
7
-37.66
152.74
21
A
ALA
19
-95.40
38.99
21
A
CYS
22
-51.60
87.85
21
A
PHE
26
-79.39
-157.58
21
A
ALA
29
-153.53
-71.87
22
A
HIS
5
-86.85
44.92
22
A
CYS
22
-59.13
85.43
22
A
PHE
26
-93.29
-156.19
22
A
ALA
29
-156.17
-40.04
23
A
HIS
5
-96.50
47.17
23
A
SER
7
-43.73
154.70
23
A
LEU
9
-40.00
111.39
23
A
CYS
22
-47.12
90.07
23
A
PHE
26
-118.16
-166.67
23
A
ALA
29
-155.21
-95.35
24
A
HIS
5
-86.80
45.87
24
A
SER
7
-34.30
147.59
24
A
ALA
19
-91.53
30.53
24
A
CYS
22
-61.87
82.46
24
A
ALA
29
-155.39
-83.69
25
A
HIS
5
-84.38
46.20
25
A
SER
7
-36.40
153.24
25
A
LEU
9
-39.12
110.67
25
A
ALA
19
-93.02
33.66
25
A
CYS
22
-59.31
83.65
25
A
PHE
26
-115.54
-164.10
25
A
ALA
29
-155.84
-48.55
26
A
HIS
5
-84.74
46.04
26
A
SER
7
-39.58
160.29
26
A
LEU
9
-38.94
100.39
26
A
CYS
22
-63.74
84.55
26
A
PHE
26
-83.45
-155.45
26
A
ALA
29
-155.56
-71.19
27
A
HIS
5
-97.57
46.90
27
A
SER
7
-47.94
157.20
27
A
LEU
9
-39.58
113.26
27
A
PRO
18
-75.01
-84.66
27
A
ALA
19
-84.93
45.62
27
A
CYS
22
-55.71
88.37
27
A
PHE
26
-110.77
-166.08
27
A
ALA
29
-155.48
-92.81
28
A
HIS
5
-85.55
45.74
28
A
SER
7
-31.73
145.10
28
A
CYS
22
-66.06
81.52
28
A
PHE
26
-97.16
-157.61
28
A
ALA
29
-155.48
-78.78
29
A
HIS
5
-84.91
45.69
29
A
SER
7
-32.58
145.31
29
A
ALA
19
-94.61
30.65
29
A
CYS
22
-62.07
80.04
29
A
PHE
26
-103.70
-158.67
29
A
ALA
29
-155.54
-86.91
30
A
HIS
5
-87.68
43.05
30
A
SER
7
-36.71
146.69
30
A
PRO
18
-75.04
-83.97
30
A
CYS
22
-62.67
86.08
30
A
PHE
26
-95.81
-156.57
30
A
ALA
29
-155.79
-40.39
31
A
HIS
5
-83.38
49.85
31
A
SER
7
-40.46
155.91
31
A
LEU
9
-43.12
96.89
31
A
CYS
22
-57.65
88.22
31
A
PHE
26
-88.50
-155.38
31
A
ALA
29
-147.82
-83.70
32
A
HIS
5
-84.04
48.00
32
A
SER
7
-38.08
153.28
32
A
LEU
9
-37.91
105.41
32
A
CYS
22
-57.81
86.54
32
A
PHE
26
-87.53
-151.09
32
A
ASN
28
-148.62
30.12
33
A
HIS
5
-89.43
47.52
33
A
SER
7
-40.16
152.59
33
A
LEU
9
-38.70
118.11
33
A
ALA
19
-95.17
31.98
33
A
CYS
22
-61.82
81.73
33
A
PHE
26
-93.27
-159.72
33
A
ALA
29
-155.49
-72.43
34
A
HIS
5
-83.72
47.46
34
A
SER
7
-39.11
153.39
34
A
ALA
19
-93.36
34.20
34
A
CYS
22
-62.24
81.02
34
A
PHE
26
-80.47
-156.58
34
A
ALA
29
-155.61
-77.70
35
A
HIS
5
-86.11
45.67
35
A
SER
7
-32.73
146.77
35
A
CYS
22
-61.42
83.96
35
A
PHE
26
-91.37
-156.86
35
A
ALA
29
-155.96
-39.05
36
A
HIS
5
-84.75
46.24
36
A
SER
7
-38.01
151.39
36
A
CYS
22
-65.76
75.49
36
A
PHE
26
-88.29
-155.90
36
A
ALA
29
-150.11
-83.73
37
A
HIS
5
-86.60
45.34
37
A
LEU
9
-55.85
95.47
37
A
ALA
19
-93.54
35.50
37
A
CYS
22
-57.72
85.97
37
A
PHE
26
-85.98
-155.97
37
A
ALA
29
-155.56
-71.24
38
A
HIS
5
-95.68
46.73
38
A
SER
7
-44.61
155.69
38
A
LEU
9
-39.27
112.28
38
A
PRO
18
-75.13
-84.81
38
A
ALA
19
-84.34
48.82
38
A
CYS
22
-59.03
88.38
38
A
ALA
29
-155.66
-52.13
39
A
HIS
5
-97.38
45.89
39
A
SER
7
-38.45
157.07
39
A
ALA
19
-92.82
30.00
39
A
CYS
22
-58.31
86.94
39
A
CYS
24
-127.07
-149.78
39
A
ARG
25
-163.62
-64.32
39
A
PHE
26
-83.09
-155.14
39
A
ALA
29
-156.13
-75.17
40
A
HIS
5
-84.28
46.50
40
A
ALA
19
-95.71
38.50
40
A
CYS
22
-53.95
88.19
40
A
CYS
24
-122.34
-152.36
40
A
ARG
25
-162.51
-63.37
40
A
PHE
26
-83.51
-154.69
40
A
ALA
29
-156.07
-76.01
SOLUTION NMR STRUCTURE OF AGRP(87-120; C105A)
1
N
N
disulf
1.997
A
CYS
1
A
SG
CYS
1
1_555
A
CYS
16
A
SG
CYS
16
1_555
disulf
2.106
A
CYS
8
A
SG
CYS
8
1_555
A
CYS
22
A
SG
CYS
22
1_555
disulf
1.993
A
CYS
15
A
SG
CYS
15
1_555
A
CYS
33
A
SG
CYS
33
1_555
disulf
1.982
A
CYS
24
A
SG
CYS
24
1_555
A
CYS
31
A
SG
CYS
31
1_555
SIGNALING PROTEIN
RATIONAL PROTEIN DESIGN, ICK, INHIBITOR CYSTINE KNOT, AGRP, AGOUTI-RELATED PROTEIN, MELANOCORTIN, SIGNALING PROTEIN
AGRP_HUMAN
UNP
1
87
O00253
CVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCR
87
120
1MR0
1
34
O00253
A
1
1
34
1
CYS
engineered mutation
ALA
19
1MR0
A
O00253
UNP
105
19
2
anti-parallel
A
THR
21
A
THR
21
A
CYS
24
A
CYS
24
A
CYS
31
A
CYS
31
A
ARG
34
A
ARG
34
1
P 1